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TITLE AND SUBTITLE
Prevention of Radiation-Induced Breast Cancer By AmifOStine 6. AUTHOR(S) Michael M. Weil, Ph.D. Exposure to ionizing radiation at doses used in cancer radiotherapy and diagnostic radiology can increase breast cancer risk in women less than 45 years of age. Amifostine is a currently used cytoprotective agent. In addition to its cytoprotective effect, amifostine has been reported to inhibit radiation-induced mutagenesis in cultured cells and to protect against radiation-induced tumorigenesis in rodent model systems. This project is a pre-clinical study designed to determine if amifostine might be effective in preventing breast cancer initiation by medical exposures to ionizing radiation. The experiments will determine if amifostine is protective in a murine model of breast cancer initiation and, if so, determine the optimum dose, route and timing for its administration. The fnst year's objective was to test a high dose of amifostine administered I.P. prior to inradiation for reduction of ductal dysplasia in an outgrowth assay. In the fu:st year 412 mammary fat pads were transplanted with mammary epithehal cells from irradiated donors. Of these, 306 have been harvested and examined as whole mounts. No dysplasias have been seen, but due to the low outgrowth frequency no conclusions can be drawn yet on the effectiveness of amifostine.
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
SUBJECT TERMS
Prevention of diagnostic and treatment induced long-term morbidity, chemoprevention, radiation-induced breast cancer Historical medical exposures to radiation have been found to increase breast cancer risk. Some currently used diagnostic radiology and cancer radiotherapy procedures deliver doses to mammary tissue in susceptible girls and women that is comparable to the historical exposures. The research supported through DAMD17-02-1-0460 is designed to determine if a chemoprotective agent, amifostine, can prevent radiation-induced ductal dysplasias that progress to mammary tumors. The research design takes advantage of an inbred mouse strain that is susceptibile to radiation-induced mammary tumors.
BODY:
The approved statement of work is: Half an hour later the mouse will be irradiated to the whole body with 1 Gy in a ^^^Cs small animal irradiator. After six weeks the donor will be sacrificed and the mammary epithelial cells will be harvested. The mammary epithelial cells will be transplanted into cleared mammary fat pads in 20 recipients (two fat pads per recipient). Ten weeks later the fat pads will be harvested from the recipients and processed as whole mounts. The whole mounts will be examined for ductal dysplasias and any suspected dysplasias will be confirmed by histological examination. c. The results of these experiments will indicate if a high dose of amifostine can reduce the frequency of radiation-induced ductal dysplasias in a susceptible mouse strain. d. Since amifostine has been shown to be active against radiation-induced tumorigenesis in other rodent models we anticipate that it will be effective in reducing radiation-induced ductal dysplasia in this system. However, if it is not we will screen other sensitive mouse sfrains (Weil in press) and other chemopreventive agents, including N-acetylcysteine and captopril. b. Methods: As described in Task I, except decreasing doses of amifostine will be used. c. The results of these experiments will determine the lowest dose of amifostine, down to 1 mg/kg, that will reduce the frequency of radiation-induced ductal dysplasia. d. We do not anticipate problems with this task. c.
d.
Methods: As described in Task 1, except amifostine will be delivered by gavage. The results of these experiments will determine if amifostine administered p.o. will reduce the frequency of radiation-induced ductal dysplasia.
If oral administration is ineffective we will examine other routes such as subcutaneous or intramuscular injection. We will also test compounds similar to amifostine but more suited to oral administration such as WR-3689, WR151327, N-acetylcysteine and captopril.
The task for the first year was to determine if high dose amifostine administered IP. prevents radiation-induced ductal dysplasia. The table reveals two shortcomings. The first is a technical matter, the low percentage of fat pads that have outgrowths. Ideally this number should be 70% but in these experiments it was only 24%. We have seen this before and other groups have also experienced similar reductions in outgrowth frequency. The decreased efficiencies have been fransient and their cause(s) remain unknown. Although we had normal mammary epithelial cell yields from the donors and good cell viabilities we have, never the less, replaced all the reagents used in the assay. A second shortcoming is that only 412 transplants were made of the 800 proposed. Part of this was due to delays in setting up accounts and vendor shortages of BALB/cByJ mice.
